KBY Biotech Indexv0.0.34
Search
← Pipeline|SIE-9908

SIE-9908

Phase 3
By Sierra Oncology (GSK)
Source: Trial-derived·Trials: 2
Modality
Cell Therapy
MOA
PD-1i
Target
VEGF
Pathway
Complement
Ovarian Ca
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
~Oct 2018
→ ~Jan 2020
Phase 3
Apr 2020
→ Feb 2030
Phase 3Current
NCT03150429
168 pts·Ovarian Ca
2020-04→2030-02·Active
NCT08165341
1,458 pts·Ovarian Ca
2023-06→2030-02·Active
1,626 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-02-133.9y awayPh3 Readout· Ovarian Ca
2030-02-203.9y awayPh3 Readout· Ovarian Ca
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Active
P3
Active
Catalysts
Ph3 Readout
2030-02-13 · 3.9y away
Ovarian Ca
Ph3 Readout
2030-02-20 · 3.9y away
Ovarian Ca
Active|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT03150429Phase 3Ovarian CaActive168PANSS
NCT08165341Phase 3Ovarian CaActive1458LiverFat
Competitors (10)
DrugCompanyPhaseTargetMOA
ZanuderotideNovartisPhase 1/2VEGFCD3xCD20
GSK-7987GSKPhase 3MDM2PD-1i
TAK-8730TakedaPhase 2VEGFFXIai
GIL-2011Gilead SciencesPreclinicalVEGFSOS1i
BemazumabRegeneronPhase 1VEGFTROP-2 ADC
NirabrutinibBioNTechPhase 2/3CDK2PD-1i
CevinaritideGenmabPhase 2/3DLL3PD-1i
PemicapivasertibLegend BiotechPhase 3VEGFCDK4/6i
SematapinarofLegend BiotechNDA/BLAVEGFCGRPant
LEG-6533Legend BiotechNDA/BLAVEGFPARPi